Autopsy report · NCT06535009

Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors

“Due to strategic reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 5 months after it had already started.
• Ran for about 3 years 1 month before it stopped.
• 25 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Ono Pharmaceutical Co., Ltd.

Sponsor type

Industry

Conditions

Solid Tumor

Interventions

ONO-7914; ONO-4538

Participants

25

Sites

1

Countries

Japan

Trials that died the same way

• Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
  “Strategic reasons” (86% match in meaning)
• A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
  “For Strategic Reasons” (84% match in meaning)
• Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  “Due to business reasons” (82% match in meaning)
• Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia
  “Due to corporate strategic adjustment.” (78% match in meaning)
• S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
  “Strategic development reasons” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.